????????
K.Cusi,S.Isaacs,D.Barbetal.EndocrinePractice28(2022)528e562
370.MandeliaC,KabbanyMN,WorleyS,ConjeevaramSelvakumarPK.Perfor-assesssafety,tolerability,pharmacokinetics,andpharmacodynamics.Pediatr
mancecharacteristics,intra-andinter-operatoragreementoftransientObes.2019;14(5),e12495.
elastographyinpediatricnonalcoholicfattyliverdisease.JPediatrGastro-378.DanneT,BiesterT,KapitzkeK,etal.Liraglutideinanadolescentpopulation
enterolNutr.2021;72(3):430e435.withobesity:arandomized,double-blind,placebo-controlled5-weektrialto
371.FitzpatrickE,QuagliaA,VimalesvaranS,BassoMS,DhawanA.Transientelas-assesssafety,tolerability,andpharmacokineticsofliraglutideinadolescents
tographyisausefulnoninvasivetoolfortheevaluationofbrosisinpaediatricaged12-17years.JPediatr.2017;181:146e153.e3.
chronicliverdisease.JPediatrGastroenterolNutr.2013;56(1):72e76.379.PetriKC,JacobsenLV,KleinDJ.Comparableliraglutidepharmacokineticsin
372.NobiliV,VizzuttiF,ArenaU,etal.Accuracyandreproducibilityoftransientpediatricandadultpopulationswithtype2diabetes:apopulationpharma-
elastographyforthediagnosisofbrosisinpediatricnonalcoholicsteatohe-cokineticanalysis.ClinPharmacokinet.2015;54(6):663e670.
patitis.Hepatology.2008;48(2):442e448.380.KellyAS,AuerbachP,Barrientos-PerezM,etal.Arandomized,controlledtrial
373.SchwimmerJB,Ugalde-NicaloP,WelshJA,etal.Effectofalowfreesugardietofliraglutideforadolescentswithobesity.NEnglJMed.2020;382(22):
vsusualdietonnonalcoholicfattyliverdiseaseinadolescentboys:aran-2117e2128.
domizedclinicaltrial.JAMA.2019;321(3):256e265.381.TamborlaneWV,Barrientos-PerezM,FainbergU,etal.Liraglutideinchildren
374.LeeS,BachaF,HannonT,KukJL,BoeschC,ArslanianS.Effectsofaerobicandadolescentswithtype2diabetes.NEnglJMed.2019;381(7):637e646.
versusresistanceexercisewithoutcaloricrestrictiononabdominalfat,382.CentersforDiseaseControlandPrevention.Deningchildhoodweightstatus
intrahepaticlipid,andinsulinsensitivityinobeseadolescentboys:aran-BMIforchildrenandteens.AccessedDecember17,2021.https://www.cdc.
domized,controlledtrial.Diabetes.2012;61(11):2787e2795.gov/obesity/basics/childhood-dening.html?CDC_AA_refVal?https%3A%2F%2F
375.LavineJE,SchwimmerJB,VanNattaML,etal.EffectofvitaminEormetforminwww.cdc.gov%2Fobesity%2Fchildhood%2Fdening.html
fortreatmentofnonalcoholicfattyliverdiseaseinchildrenandadolescents:383.ArmstrongS,LazorickS,HamplS,etal.Physicalexaminationndingsamong
thetonicrandomizedcontrolledtrial.JAMA.2011;305(16):1659e1668.childrenandadolescentswithobesity:anevidence-basedreview.Pediatrics.
376.MannJP,TangGY,NobiliV,ArmstrongMJ.Evaluationsoflifestyle,2016;137(2),e20151766.
dietary,andpharmacologictreatmentsforpediatricnonalcoholicfattyliver384.IngeTH,CourcoulasAP,JenkinsTM,etal.Five-yearoutcomesofgastric
disease:asystematicreview.ClinGastroenterolHepatol.2019;17(8):bypassinadolescentsascomparedwithadults.NEnglJMed.2019;380(22):
1457e1476.e7.2136e2145.
377.MastrandreaLD,WittenL,CarlssonPetriKC,HalePM,HedmanHK,385.MancoM,MoscaA,DePeppoF,etal.Thebenetofsleevegastrectomyin
RiesenbergRA.Liraglutideeffectsinapaediatric(7-11y)populationwithobeseadolescentsonnonalcoholicsteatohepatitisandhepaticbrosis.
obesity:arandomized,double-blind,placebo-controlled,short-termtrialtoJPediatr.2017;180:31e37.e2.
562 |
|
